<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03307512</url>
  </required_header>
  <id_info>
    <org_study_id>Samba-AC</org_study_id>
    <nct_id>NCT03307512</nct_id>
  </id_info>
  <brief_title>PK and PD Profile of Dance 501 in Healthy, Non-diabetic Subjects With Mild to Moderate Asthma or COPD</brief_title>
  <official_title>Samba-AC: A Randomized, Open-Label, Cross-Over Study to Investigate the PK and PD Profiles of Dance 501 (Human Insulin Inhalation Solution and Inhaler) in Healthy Subjects and Non-Diabetic Subjects With Mild to Moderate Asthma or COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dance Biopharm Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>WCCT Global</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dance Biopharm Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a randomized, open-label, active-controlled, single dose crossover study with
      either three or four treatment periods. Investigational treatment is with Dance 501 Human
      Insulin Inhalation Solution (Dance 501) and the comparator is Insulin Lispro (Humalog®).

      Target population will be Non-Diabetic individuals with mild to moderate asthma or chronic
      obstructive pulmonary disease (COPD) and non-diabetic individuals without underlying lung
      disease (healthy subjects).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The PK and PD profile of Dance 501 (Human Insulin Inhalation Solution and Inhaler) will be
      compared to subcutaneous injection of insulin lispro.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Termination due to incomplete enrollment; planned data analysis not performed
  </why_stopped>
  <start_date type="Actual">February 6, 2018</start_date>
  <completion_date type="Actual">August 30, 2019</completion_date>
  <primary_completion_date type="Actual">July 30, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Randomized, open-label, cross-over design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the insulin curve (AUC)</measure>
    <time_frame>10 hours</time_frame>
    <description>Area under the insulin curve (AUC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the glucose infusion rate curve (GIR)</measure>
    <time_frame>10 hours</time_frame>
    <description>Area under the glucose infusion rate curve (GIR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the insulin curve following inhalation of salbutamol</measure>
    <time_frame>10 hours</time_frame>
    <description>Area under the insulin curve following inhalation of salbutamol in subjects with asthma</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Safety and Tolerability</condition>
  <arm_group>
    <arm_group_label>Dance 501</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dance 501(Human Insulin Inhalation Solution and Inhaler) will be administered by inhalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin Lispro</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Insulin Lispro (Humalog®) will be administered by subcutaneous injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>inhaled human insulin</intervention_name>
    <description>Dance 501 (Human Insulin Inhalation Solution and Inhaler) will be administered by inhalation</description>
    <arm_group_label>Dance 501</arm_group_label>
    <other_name>Dance 501</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Lispro (Humalog U-100)</intervention_name>
    <description>Insulin Lispro (Humalog U-100) will be administered by subcutaneous injection</description>
    <arm_group_label>Insulin Lispro</arm_group_label>
    <other_name>Lispro</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  non-diabetic subjects with asthma, or COPD. Non-smokers or smokers quit at least 6
             months prior to enrollment. BMI &lt;= 35 kg/m2. Fasting blood glucose &lt;= 125 mg/dL.

        Exclusion Criteria:

          -  pulmonary disorder other than asthma or COPD. Upper respiratory within previous 4
             weeks. Significant exacerbation of asthma or COPD symptoms. Hospitalization for asthma
             or COPD within previous 3 months. Clinically significant medical condition. Current
             medications interfering with glucose metabolism.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy S Bailey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AMCR</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>WCCT</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>October 2, 2017</study_first_submitted>
  <study_first_submitted_qc>October 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 11, 2017</study_first_posted>
  <last_update_submitted>September 11, 2019</last_update_submitted>
  <last_update_submitted_qc>September 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>inhaled insulin</keyword>
  <keyword>asthma</keyword>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin Lispro</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

